Oculis Holding AG (OCS) Tax Provisions (2022 - 2026)
Oculis Holding AG (OCS) posted quarterly Tax Provisions of $125146.5 for Q1 2026, up 1707.38% year-over-year from $6924.2 in Q1 2025, and up 100.12% quarter-over-quarter from -$102.4 million in Q4 2025.
Oculis Holding AG (OCS) Tax Provisions (2022 - 2026) Analysis & Trends
Oculis Holding AG's Tax Provisions history runs 5 years deep, the most recent figure standing at $125146.5 for Q1 2026.
- In Q1 2026, Tax Provisions rose 1707.38% year-over-year to $125146.5; the TTM figure through Mar 2026 stood at -$118.5 million (down 476.59% YoY), while the FY2025 annual figure was $224339.9, up 23.35% from the prior year.
- Tax Provisions for Q1 2026 stood at $125146.5, up from -$102.4 million in the prior quarter.
- The five-year high for Tax Provisions was $271682.2 in Q4 2024, with the low at -$102.4 million in Q4 2025.
- The 5-year median for Tax Provisions is -$20479.8 (2024), against an average of -$8.7 million.
- The sharpest annual moves came in 2023 and 2025: Tax Provisions soared 2213.88% in 2023, then sank 37777.55% in 2025.
- Oculis Holding AG's Tax Provisions stood at $14532.3 in 2022, then grew by 0.85% to $14655.6 in 2023, then jumped by 1753.78% to $271682.2 in 2024, then tumbled by 37777.55% to -$102.4 million in 2025, then soared by 100.12% to $125146.5 in 2026.
- Business Quant data shows OCS's Tax Provisions at $125146.5 in Q1 2026, -$102.4 million in Q4 2025, and -$16.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 292.00 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 230.90 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 59.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 75.45 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 267.73 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 13.31 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.90 Mn |
| 10 | Oculis Holding AG | 879.09 Mn | 590.21 Mn | - | 7,591.43 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 7,591.43 |
| Mar 31, 2026 | 125,146.46 |
| Dec 31, 2025 | -102.36 Mn |
| Sep 30, 2025 | -16.25 Mn |
| Jun 30, 2025 | 28,989.37 |
| Mar 31, 2025 | -7,785.75 |
| Dec 31, 2024 | 271,682.20 |
| Sep 30, 2024 | -20.78 Mn |
| Jun 30, 2024 | -33,173.80 |
| Mar 31, 2024 | -34,370.47 |
| Dec 31, 2023 | 14,655.61 |
| Sep 30, 2023 | 131,329.70 |
| Jun 30, 2023 | -126,788.01 |
| Mar 31, 2023 | -134,064.16 |
| Dec 31, 2022 | 14,532.31 |
| Sep 30, 2022 | -6,212.74 |
| Jun 30, 2022 | -43,608.31 |